EWTX — Edgewise Therapeutics, Inc. stock price, charts and financials
QT65Edgewise Therapeutics, Inc.Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
38.38
-0.05-0.13%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 107.59M | Perf Week | -5.90% |
| Market Cap | 4.13B | Forward P/E | - | EPS next Y | -1.66 | Insider Trans | -0.54% | Shs Float | 79.59M | Perf Month | -1.84% |
| Enterprise Value | 4.11B | PEG | 3.41 | EPS next Q | - | Inst Own | 115.16% | Short Float | 12.66% | Perf Quarter | 24.13% |
| Income | -176.97M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 6.87 | Perf Half Y | 33.53% |
| Sales | 0.00 | P/B | 8.35 | EPS next Y | 16.30% | ROA | -33.94% | Short Interest | 10.07M | Perf YTD | 54.83% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -32.55% | 52W High | 48.34 -20.60% | Perf Year | 170.06% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -40.15% | 52W Low | 12.28 212.44% | Perf 3Y | 431.54% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.59% 5.97% | Perf 5Y | 91.00% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -14.48% | Oper. Margin | 0.00% | ATR (14) | 2.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 22.61 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 46.45 | Recom | 2.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 22.61 | EPS Q/Q | -6.98% | SMA20 | -6.40% | Beta | 0.28 | Target Price | 49.09 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | - | SMA50 | 0.45% | Rel Volume | 0.81 | Prev Close | 38.43 |
| Employees | 154 | LT Debt/Eq | 0.01 | Earnings | Aug 06 | SMA200 | 29.32% | Avg Volume | 1.41M | Price | 38.38 |
| IPO Date | Mar 26, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 5.08% - | Net Debt/EBITDA | 0.17 | Volume | 1,142,809 | Change | -0.13% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-20-26 | Reiterated | Evercore ISI Group | Outperform | $45 → $55 |
| Jul-09-26 | Initiated | Oppenheimer | Outperform | $51 |
| Jul-06-26 | Reiterated | Guggenheim | Buy | $51 |
| Jun-17-26 | Reiterated | Goldman Sachs | Neutral | $20 → $32 |
| Jun-17-26 | Reiterated | RBC Capital | Outperform | $48 → $59 |
| Jun-16-26 | Reiterated | Leerink Partners | $50 → $52 | |
| Jun-02-26 | Reiterated | RBC Capital | Outperform | $42 → $48 |
| Jun-02-26 | Reiterated | HC Wainwright & Co. | Buy | $45 |
| Jun-01-26 | Reiterated | Raymond James | $52 → $66 | |
| May-06-26 | Reiterated | Truist Financial | Buy | $46 → $52 |
Latest News
Jul-20-26
Jul-20-2608:57AM
Jul-13-26
Jul-13-2608:30AM
08:30AM
Jul-09-26
Jul-09-2609:32AM
Jul-06-26
Jul-06-2610:09AM
Jul-01-26
Jul-01-2608:00AM
Jun-18-26
Jun-17-26
Jun-17-2611:02AM
06:22AM
03:43AM
Jun-16-26
11:57AM
08:05AM
Company
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Ownership
Total institutional ownership115.16%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | -2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 40 | 32 | 23 | 18 | 11 | 2 | 1 | |
| Research and Development | 151 | 127 | 91 | 54 | 32 | 15 | 9 | |
| Other Operating Expense | -2 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -191 | -159 | -114 | -72 | -43 | -17 | -10 | |
| Interest Expense | 0 | 0 | 0 | 4 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 24 | 25 | 14 | 8 | 0 | 0 | 0 | |
| Net Income Before Taxes | -168 | -134 | -100 | -68 | -43 | -17 | -10 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -168 | -134 | -100 | -68 | -43 | -17 | -9 | |
| Net Income From Continuing Operations | -168 | -134 | -100 | -68 | -43 | -17 | -10 | |
| Net Income | -168 | -134 | -100 | -68 | -43 | -17 | -9 | |
| EPS (Recurring) | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 | |
| EPS (Basic, Before Extraordinaries) | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 | |
| EPS (Diluted) | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 | |
| EBITDA | -166 | -132 | -98 | -63 | -43 | -17 | -10 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 103 | 92 | 64 | 54 | 50 | 49 | 49 | |
| Market Capitalization | 2,556 | 2,456 | 700 | 483 | 764 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Russell Alan J | Chief Scientific Officer | Jul 01 '26 | Option Exercise | 0.36 | 200,000 | 71,195 | 224,555 | Jul 02 |
| Russell Alan J | Chief Scientific Officer | Jul 01 '26 | Sale | 39.41 | 200,000 | 7,881,402 | 24,555 | Jul 02 |
| Donovan Joanne M. | CMO | May 05 '26 | Option Exercise | 7.08 | 50,000 | 354,000 | 54,367 | May 05 |
| Donovan Joanne M. | CMO | May 05 '26 | Sale | 38.57 | 50,000 | 1,928,400 | 4,367 | May 05 |
| Donovan Joanne M. | CMO | May 04 '26 | Sale | 31.29 | 5,230 | 163,663 | 4,367 | May 05 |
| Donovan Joanne M. | CMO | Apr 01 '26 | Option Exercise | 7.08 | 28,662 | 202,927 | 38,259 | Apr 02 |
| Donovan Joanne M. | CMO | Apr 01 '26 | Sale | 32.31 | 28,662 | 926,095 | 9,597 | Apr 02 |
| Donovan Joanne M. | CMO | Mar 31 '26 | Option Exercise | 7.08 | 21,338 | 151,073 | 30,935 | Mar 31 |
| Donovan Joanne M. | CMO | Mar 31 '26 | Sale | 32.12 | 21,338 | 685,308 | 9,597 | Mar 31 |
| Donovan Joanne M. | CMO | Mar 27 '26 | Sale | 30.98 | 16,358 | 506,734 | 9,597 | Mar 30 |
| Edris Badreddin | Director | Jan 21 '26 | Option Exercise | 1.47 | 115,471 | 170,265 | 135,291 | Jan 23 |
| Edris Badreddin | Director | Jan 21 '26 | Sale | 29.44 | 115,471 | 3,399,467 | 19,820 | Jan 23 |
| Russell Alan J | Chief Scientific Officer | Nov 12 '25 | Option Exercise | 0.18 | 100,000 | 18,000 | 123,400 | Nov 13 |
| Russell Alan J | Chief Scientific Officer | Nov 12 '25 | Sale | 21.12 | 100,000 | 2,112,450 | 23,400 | Nov 13 |
| Fox Jonathan C | Director | Nov 11 '25 | Buy | 18.64 | 10,700 | 199,403 | 23,702 | Nov 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.